• DOI:10.1016/j.pharmthera.2018.06.012
Corpus ID: 49602956

Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences

@article{Aringhieri2018MolecularTO,
  title={Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences},
  author={Stefano Aringhieri and Marco Carli and Shivakumar Kolachalam and V. Verdesca and Enrico Cini and M. Rossi and P. McCormick and G. Corsini and R. Maggio and M. Scarselli},
  journal={Pharmacology \& Therapeutics},
  year={2018},
  volume={192},
  pages={20–41}
}

• Stefano Aringhieri, Marco Carli, +7 authors M. Scarselli
• Published 2018
• Medicine
• Pharmacology & Therapeutics

ABSTRACT The introduction of atypical antipsychotics (AAPs) since the discovery of its prototypical drug clozapine has been a revolutionary pharmacological step for treating psychotic patients as these allow a significant recovery not only in terms of hospitalization and reduction in symptoms severity, but also in terms of safety, socialization and better rehabilitation in the society. Regarding the mechanism of action, AAPs are weak D2 receptor antagonists and they act beyond D2 antagonism… Expand